Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | GLI1 | P08151 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Proline SCHEMBL15210884 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL20897288 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| D-Proline SCHEMBL5665276 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL19947289 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL3442547 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL499448 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL499449 | 1.00 | NOS2 (0.42) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL28093320 | 0.96 | NOS2 (0.40) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL28101824 | 0.96 | NOS2 (0.40) | NOS2NOS3NOS1MEN1BLM | |
| Proline SCHEMBL1828861 | 0.95 | NOS2 (0.39) | NOS2NOS3NOS1MEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732378-B2 | Mass labels | ELECTROPHORETICS LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20070269832-A1 | Novel affinity labels | IMMUNOCHEMISTRY TECHNOLOGIES, LLC | 2007-11-22 | — | — | US | disclosed |
| EP-1425586-B1 | MASS LABELS | ELECTROPHORETICS LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20060148023-A1 | Affinity labeling of serine proteases for simultaneous detection of multiple serine protease activity levels | IMMUNOCHEMISTRY TECHNOLOGIES, LLC | 2006-07-06 | — | — | US | disclosed |
| US-20050136492-A1 | Affinity labeling of enzymes for detection of enzyme activity level in living cells | IMMUNOCHEMISTRY TECHNOLOGIES, LLC | 2005-06-23 | — | — | US | disclosed |
| US-20050048489-A1 | Mass labels | ELECTROPHORETICS LIMITED (GB) | 2005-03-03 | — | — | US | disclosed |
| EP-1425586-A2 | MASS LABELS | Xzillion GmbH & CO.KG (DE) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003059877-A2 | NOVEL AFFINITY LABELS | IMMUNOCHEMISTRY TECHNOLOGIES, LLC (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060466-A2 | AFFINITY LABELING OF SERINE PROTEASES FOR SIMULTANEOUS DETECTION OF MULTIPLE SERINE PROTEASE ACTIVITY LEVELS | IMMUNOCHEMISTRY TECHNOLOGIES, LLC (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003058194-A2 | AFFINITY LABELING OF ENZYMES FOR DETECTION OF ENZYME ACTIVITY LEVEL IN LIVING CELLS | IMMUNOCHEMISTRY TECHNOLOGIES, LLC (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003025576-A2 | MASS LABELS | XZILLION GMBH & CO. KG (DE) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070269832-A1 | Novel affinity labels | ANPEP, SLC7A1, DNPEP | NOS2 4478/4885NOS3 4406/4885NOS1 4118/4885 |
| US-20050048489-A1 | Mass labels | SUMO1, SUMO2, SUMO3 | NOS2 2897/4885NOS3 2777/4885NOS1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.